US FDA Grants Moleculin Orphan Drug Designation of WP1122 to Treat Glioblastoma Multiforme
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation of WP1122 to Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, for the treatment of Glioblastoma Multiforme (GBM). Walter Klemp, chairman and CEO of Moleculin Biotech, Inc., said the receipt of Orphan Drug Designation is represents an important milestone for their promising WP1122 development […]
Continue Reading